Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Accounts Payables (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Accounts Payables for 6 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables fell 36.9% year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Sep 2025, down 36.9%, and an annual FY2024 reading of $3.2 million, down 13.8% over the prior year.
  • Accounts Payables was $1.7 million for Q3 2025 at Ovid Therapeutics, down from $4.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $7.1 million in Q4 2021 and bottomed at $909523.0 in Q2 2021.
  • Average Accounts Payables over 5 years is $3.0 million, with a median of $3.1 million recorded in 2021.
  • The sharpest move saw Accounts Payables plummeted 80.37% in 2021, then soared 407.58% in 2022.
  • Year by year, Accounts Payables stood at $7.1 million in 2021, then crashed by 72.6% to $2.0 million in 2022, then skyrocketed by 89.61% to $3.7 million in 2023, then decreased by 13.8% to $3.2 million in 2024, then crashed by 46.43% to $1.7 million in 2025.
  • Business Quant data shows Accounts Payables for OVID at $1.7 million in Q3 2025, $4.0 million in Q2 2025, and $2.0 million in Q1 2025.